News for Healthier Living
ESMO 2026: New Targeted Therapy Improved Survival for Patients with KRAS-Mutated Lung Cancer
Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS targeted therapy divarasib, according to researchers from The University of Texas MD Anderson Cancer Center.
October 25, 2026
November 1 2026October 30 2026October 29 2026October 28 2026October 27 2026October 26 2026October 25 2026October 24 2026October 23 2026October 22 2026October 21 2026October 20 2026October 19 2026
|
|
|
|
|